Patents by Inventor Thomas Ebensen
Thomas Ebensen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240058438Abstract: The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.Type: ApplicationFiled: January 19, 2023Publication date: February 22, 2024Inventors: Michael Houghton, Abdolamir Landi, Carlos A. Guzman, Thomas Ebensen, Darren Hockman, John L. Law, Michael Logan
-
Publication number: 20230129118Abstract: Phytosphingosine derivatives suitable as adjuvants in immune stimulation, pharmaceutical compositions comprising such compounds and the medical use of the compounds and/or compositions in therapeutic or prophylactic methods of immune stimulation in a subject, and for use in the treatment of a disease, for which stimulation of an immune response in a subject produces a therapeutic benefit. The phytosphingosine derivative may also be used as adjuvants in vaccinating a subject. The phytosphingosine derivative may also be used in stimulating antibody production, stimulating an immune response against infection, stimulating an immune response against a cancer, or preventing and/or treating septic shock. Methods for the manufacture of the derivatives comprising an Ugi-4-component reaction (Ugi-4CR) is also disclosed.Type: ApplicationFiled: June 18, 2021Publication date: April 27, 2023Inventors: Yanira MENDEZ-GOMEZ, Bernhard WESTERMANN, Daniel GARCIA-RIVERA, Aldrin VASCO-VIDAL, Ludger WESSJOHANN, Carlos A. GUZMÁN, Thomas EBENSEN, Kai SCHULZE, Peggy RIESE, Stephanie TRITTEL
-
Patent number: 11576968Abstract: The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.Type: GrantFiled: December 15, 2020Date of Patent: February 14, 2023Assignee: The Governors of the University of AlbertaInventors: Michael Houghton, Abdolamir Landi, Carlos A. Guzman, Thomas Ebensen, Darren Hockman, John L. Law, Michael Logan
-
Publication number: 20220257752Abstract: In a first aspect, the present invention relates to cyclic dinucleotide compounds, in particular, c-di AMP for use in a method of inducing or promoting an immune response in an individual wherein said individual is a neonate or infant. The compound according to the present invention is particularly useful for use in therapeutic or prophylactic vaccination. In a further aspect, pharmaceutical compositions comprising the compound according to the present invention as an adjuvant, a pharmaceutically active ingredient for use as defined herein, in particular, as an adjuvant in a vaccine for unborn children, neonates and infants are provided. Finally, the present invention relates to a kit comprising a compound according to the present invention as an adjuvant, an antigen comprising antigenic structure as active vaccination component, in particular, to the use of said kit in a use of preventing or treating a disease.Type: ApplicationFiled: August 28, 2020Publication date: August 18, 2022Inventors: Carlos A. GUZMAN, Dario LIRUSSI, Thomas EBENSEN, Sebastian Felix WEISSMANN
-
Publication number: 20210170018Abstract: The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.Type: ApplicationFiled: December 15, 2020Publication date: June 10, 2021Inventors: Michael Houghton, Abdolamir Landi, Carlos A. Guzman, Thomas Ebensen, Darren Hockman, John L. Law, Michael Logan
-
Patent number: 10918733Abstract: The present invention relates to new lipopeptide- and lipoprotein molecules and lipopeptide- and lipoprotein-conjugates. In particular, the present invention relates to new lipopeptide- and lipoprotein molecules and lipopeptide- and lipoprotein-conjugates comprising a lipid-containing moiety representing an adjuvant moiety, a peptide or protein moiety whereby said peptide or protein moiety represents at least one antigenic structure, the antigen-moiety, and, optionally, a conjugate moiety, preferably a monodisperse polyethyleneglycol unit. Said compounds are particularly useful for therapeutic or prophylactic vaccination by mucosal or systemic administration, preferably mucosal and systemic vaccination. That is, the present invention relates in another aspect to pharmaceutical compositions comprising the compounds according to the present invention, in particular, said pharmaceutical compositions are vaccines.Type: GrantFiled: December 28, 2010Date of Patent: February 16, 2021Assignee: HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBHInventors: Thomas Ebensen, Carlos Alberto Guzman, Michael Morr, Werner Tegge
-
Patent number: 10881726Abstract: The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.Type: GrantFiled: October 5, 2017Date of Patent: January 5, 2021Assignees: The Governors of the University of Alberta, Helmholtz Center for Infection ResearchInventors: Michael Houghton, Abdolamir Landi, Carlos A. Guzman, Thomas Ebensen, Darren Hockman, John L. Law, Michael Logan
-
Patent number: 9597391Abstract: The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants and/or immunomodulators for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumors, allergies as well as for the control of fertility in human or animal populations. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants. In addition, the invention relates to its uses as active ingredients in pharmaceutical compositions.Type: GrantFiled: November 8, 2006Date of Patent: March 21, 2017Assignee: HELMHOLTZ_ZENTRUM FUER INFEKTIONSFORSCHUNG GMBHInventors: Thomas Ebensen, Michael Morr, Carlos A. Guzman
-
Publication number: 20130039939Abstract: The present invention relates to new lipopeptide- and lipoprotein molecules and lipopeptide- and lipoprotein-conjugates. In particular, the present invention relates to new lipopeptide- and lipoprotein molecules and lipopeptide- and lipoprotein-conjugates comprising a lipid-containing moiety representing an adjuvant moiety, a peptide or protein moiety whereby said peptide or protein moiety represents at least one antigenic structure, the antigen-moiety, and, optionally, a conjugate moiety, preferably a monodisperse polyethyleneglycol unit. Said compounds are particularly useful for therapeutic or prophylactic vaccination by mucosal or systemic administration, preferably mucosal and systemic vaccination. That is, the present invention relates in another aspect to pharmaceutical compositions comprising the compounds according to the present invention, in particular, said pharmaceutical compositions are vaccines.Type: ApplicationFiled: December 12, 2009Publication date: February 14, 2013Inventors: Thomas Ebensen, Carlos Alberto Guzman, Michael Morr, Werner Tegge
-
Patent number: 8257734Abstract: The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants and/or immunomodulators for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumors, allergies as well as for the control of fertility in human or animal populations. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants. In addition, the invention relates to its uses as active ingredients in pharmaceutical compositions.Type: GrantFiled: November 8, 2006Date of Patent: September 4, 2012Assignee: Helmhotlz-Zentrum Fuer Infektions-Forschung GmbHInventors: Thomas Ebensen, Michael Morr, Carlos A. Guzman
-
Patent number: 8211463Abstract: The present invention relates to adjuvants of the glycolipid type and their uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new uses of compounds useful as adjuvants for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumors and allergies. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants.Type: GrantFiled: September 6, 2007Date of Patent: July 3, 2012Assignee: Helmholtz-Zentrum Fuer Infektionsforschung GmbHInventors: Thomas Ebensen, Michael Morr, Carlos Guzman, Goetz Milkereit
-
Patent number: 8119689Abstract: Bisacyloxycysteine type conjugates have been found to be useful as adjuvants and/or immunomodulators for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumors, and allergies, as well as in the control of fertility in human or animal populations. The compounds can be administered by system or mucosal routes and are particularly useful as mucosal adjuvants. These compounds can function as active ingredients in pharmaceutical compositions.Type: GrantFiled: November 22, 2006Date of Patent: February 21, 2012Assignee: Helmholtz-Zentrum Fuer Infektionsforschung GmbHInventors: Thomas Ebensen, Michael Morr, Carlos Guzman
-
Patent number: 8053417Abstract: The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumours, allergies as well as for the control of fertility in human or animal populations. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants. In addition, the invention relates to its uses as active ingredients in pharmaceutical compositions.Type: GrantFiled: October 19, 2006Date of Patent: November 8, 2011Assignee: Helmholtz-Zentrum fuer Infektionsforschung GmbHInventors: Thomas Ebensen, Michael Morr, Carlos Guzman
-
Publication number: 20100015215Abstract: The present invention relates to adjuvants of the glycolipid type and their uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new uses of compounds useful as adjuvants for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumours and allergies. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants.Type: ApplicationFiled: September 6, 2007Publication date: January 21, 2010Inventors: Thomas Ebensen, Michael Morr, Carlos A. Guzman, Götz Milkereit
-
Publication number: 20090169609Abstract: The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants and/or immunomodulators for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumours, allergies as well as for the control of fertility in human or animal populations. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants. In addition, the invention relates to its uses as active ingredients in pharmaceutical compositions.Type: ApplicationFiled: November 8, 2006Publication date: July 2, 2009Applicant: HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMGBInventors: Thomas Ebensen, Michael Morr, Carlos A. Guzman
-
Publication number: 20090017106Abstract: The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new conjugates of the bisacyloxycysteine type useful as adjuvants and/or immunomodulators for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumours, allergies as well as for the control of fertility in human or animal populations. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants. In addition, the invention relates to its uses as active ingredients in pharmaceutical compositions.Type: ApplicationFiled: November 22, 2006Publication date: January 15, 2009Inventors: Thomas Ebensen, Michael Morr, Carlos Guzman
-
Publication number: 20080286296Abstract: The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants and/or immunomodulators for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumors, allergies as well as for the control of fertility in human or animal populations. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants. In addition, the invention relates to its uses as active ingredients in pharmaceutical compositions.Type: ApplicationFiled: November 8, 2006Publication date: November 20, 2008Inventors: Thomas Ebensen, Michael Morr, Carlos A. Guzman
-
Publication number: 20080206319Abstract: The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumours, allergies as well as for the control of fertility in human or animal populations. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants. In addition, the invention relates to its uses as active ingredients in pharmaceutical compositions.Type: ApplicationFiled: October 19, 2006Publication date: August 28, 2008Inventors: Thomas Ebensen, Michael Morr, Carlos A. Guzman